Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia / 中华男科学杂志

<p><b>OBJECTIVE</b>To study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH).</p><p><b>METHODS</b>An open, multicentral clinical trial was conducted in 100 patients with BPH. Patients received a 12-week oral administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes of efficacy include international prostatic symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine ( Ru) and prostatic volume (V). The additional indexes are quality of life score (QOL) and average urinary flow rate (Qave).</p><p><b>RESULTS</b>After a 12-week therapy, IPSS, QOL score, Qmax and Qave were significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%.</p><p><b>CONCLUSION</b>Eviprostat is a kind of safe, effective and preferable drug for treating BPH. It can improve the subjective symptoms and objective measures of the patients.</p>

Role of ethamsylate in preventing periventricular-intraventricular hemorrhage in premature infants below 34 weeks of gestation.

OBJECTIVE: To determine the role of ethamsylate in prevention of PVH-IVH in premature infants <34 weeks gestational age. DESIGN: Prospective, randomized, controlled study. METHODS: Infants less than 34 weeks gestational age were included in the trial. Neonates with congenital malformations, family history of bleeding disorders and with Apgar scores <5 at 5 minutes were excluded. Subjects were randomized into two groups--Group A infants received intravenous ethamsylate (12.5 mg/kg) six hourly for four days and Group B infants served as a control group. Regular cranial ultrasounds to detect the presence of PVH-IVH were done between days 3-5, 10-14 and 28-30 of post natal age, and before hospital discharge in all infants and weekly in infants detected to have PVH-IVH on earlier scans. Various antenatal and postnatal factors known to affect the incidence of PVH-IVH were recorded. RESULTS: A total of 192 infants underwent the trial, 93 in Group A and 99 in Group B. Antenatal corticosteroids (1 or 2 doses) were administered to 32 ( 34.4%) and 36 (36.3%) women in Group A and Group B, respectively. None of the mothers received phenobarbitone, vitamin K or indomethacin antenatally and none of the infants received phenobarbitone, vitamin E or indomethacin postnatally during the study period. PVH-IVH was seen in 26 infants in Group A, of which Grade I IVH occurred in 9, Grade II in 14, Grade III in 2 and Grade IV in one infant. Twenty-nine infants had PVH-IVH in Group B of which 11 had Grade I, 15 Grade II and 3 Grade III. None of the differences were statistically significant. CONCLUSION: Postnatal administration of ethamsylate did not decrease the incidence of PVH-IVH in the study infants.

comparative study of clinical and histopathological response of different modalities of therapy used in the management of IUCD induced menorrhagia

Removal of IUCD as a result of menorrhagic side effects was reported to occur in 8% of IUCD users. In this study, 75 women with Cu. T. 200 for more than 3 months with irregular menstrual bleeding were treated ether by metronidazole [Flagyl], mefenamic acid [Ponstan] ehamsylate [Dicynone] or a combination of these 3 drugs for 3 consecutive cycles. Endometrial biopsy was carried out before and after therapy to identify any possible changes in the histopathological pattern. The use of combined treatment of all the 3 drugs gave the most significant result in reducing the amount but not the duration of the flow in 47.4% of patients

Prevençäo da hemorragia periventricular-intraventricular do prematuro: um enfoque farmacológico / Prevention of periventricular and intraventricular haemorrhage of the premature: a pharmacological approach

Apesar dos avanços verificados nos últimos anos em terapia neonatal intensiva, as hemorragias do sistema nervoso central ainda se constituem em expressivas causas morbi-mortalidade para os pequenos prematuros com menos de 35 semanas de idade gestacional e peso de nascimento inferior a 1500g. Sua ocorrência nas primeiras horas de vida pós-natal tem motivado sucessivas pesquisas no sentido de encontrar algum agente que, administrado precocemente, possa preveni-las. Discorre-se nesta revisäo sobre o uso de fenobarbital, brometo de pancurônio, etamsilato, vitamina E, indometacina e teofilina na prevençäo das hemorragias do sistema nervoso central, näo identificando nenhum de eficácia inteiramente comprovada

Histopathological study of the effects of ethamsylate [dicynone] on rabbit's eye

The effects of intacameral injection of 0.3 ml of dicynone on ocular tissues of rabbits were studied. Progressive atrophic changes affecting the cornea, iris, ciliary body and the optic nerve of rabbits' eyes were observed. The details of these atrophic changes were discussed. There was also a lowering of the intra-ocular pressure of the rabbits' eyes after dicynone Injection into their anterior chamber